Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine: A retrospective cost-efficacy analysis

PharmacoEconomics

Volumn 10, Issue 1, 1996, Pages 59-71

  Payne, Katherine ^a,c   Kozma, Chris M ^a   Lawrence, Bryan J ^b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Sandoz Pharma Ltd   (Switzerland)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROERGOTAMINE MESILATE; SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; MALE; MIGRAINE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029956285     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199610010-00006     Document Type: Article

References (20)

1. Rappaport AM. Recurrent migraine: cost-effective care. Neurology 1994; 44 Suppl. 3: S25-8
2. Winner P, Ricalde O, LeForce B, et al. A double-blind study of subcutaneous dihydroergotamine versus subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53: 180-4
3. Kozma CK, Mauch RP, Reeder CE, et al. A literature review comparing the economic, clinical and humanistic attributes of dihydroergotamine and sumatriptan. Clin Ther 1994; 16 (6): 1037-51
4. Welch KMA. Drug therapy of migraine. N Engl J Med 1993; 329 (20): 1476-83
5. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the national health interview survey. Headache 1993; 33: 29-35
6. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalgia 1988; 8 Suppl. 7: 1-96
7. Ziegler DK, Hassanein RS. Specific headache phenomena: their frequency and coincidence. Headache 1990; 30: 152-6
8. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalgia 1992; 12: 221-8
9. Silberstein SD, Lipton RB. Epidemiology of migraine. Neuroepidemiology 1993; 12: 179-94
10. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States: relation to income, race and other sociodemographic factors. JAMA 1992; 267 (1): 64-9
11. Friedman MD, Friedman DA. DHE 45 in the treatment of migraine: preliminary clinical observations. Ohio State Med J 1945; 41 (12): 1099-100
12. 'DHE 45' (dihydroergotamine mesylate) injection product information. East Hanover (NJ): Sandoz Pharmaceuticals Corporation, 1993 Apr
13. Klapper JA, Stanton J. Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches. Headache 1992; 32 (1): 21-3
14. 'Imitrex' (sumatriptan succinate) injection product information. Research Triangle Park (NC): Cerenex Pharmaceuticals, 1994 May
15. Sumatriptan, serotonin and money [editorial]. Lancet 1992; 339: 151-2
16. Kenyon J, editor. Optimum treatment of acute migraine and the place of sumatriptan in therapy. Drug Ther Perspect 1993; 1 (1): 1-4
17. Average Wholesale Prices. Medi-Span Inc: 1995 Jul 1
18. Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics. Cincinnati (OH): Harvey Whitney Books Company, 1991: 89
19. US Bureau of the Census. Statistical Abstract of the United States: 1993. 113th ed. Washington, DC: The Reference Press, 1993
20. Ukens C. Pharmacist salaries: who's getting the bigger bite? Drug Topics 1993; 137 (7): 42-54